TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25751386
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution group (treatment group)
Study: 23245621
Drug: Optimal standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal standard therapy
Study: 21676008
Drug: Pharmacobehavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacobehavioral treatment
Study: 17672828
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) using recombinant human ASB (rhASB)
Study: 14959954
Drug: Bisphosphonate infusion
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate infusion (pamidronate or clodronate)
Study: 8678396
Drug: Warfarin vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin vs Aspirin in patients older than 75 years
Study: 6693580
Drug: lorazepam infusion
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lorazepam infusion at two different rates
Study: 15037537
Drug: Chlorthalidone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (50 mg/d)
Study: 2877644
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy with chlorthalidone
Study: 28152655
Drug: del Nido
Normalized name: Del Nido Cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: del Nido (DN) solution
Study: 28152655
Drug: modified St.
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified St. Thomas' (MST) cardioplegia solution
Study: 11029345
Drug: pH-corrected group
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-corrected group (THAM administered)
Study: 11029345
Drug: pH-uncorrected group
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-uncorrected group (no THAM administered)
Study: 8816034
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no additional iron treatment)
Study: 1486738
Drug: 1 alpha-hydroxy
Normalized name: alpha hydroxy acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 alpha-hydroxy vitamin D3 (1 microgram/day) and 500 mg of calcium
Study: 30865304
Drug: Preventure program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventure program (cognitive behavioral therapy-based group sessions targeting personality risk profiles)
Study: 23415907
Drug: Total glucosides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total glucosides of paeony (TGP) in combination with methotrexate (MTX 10 mg/week) and leflunomide (LEF 20 mg/day)
Study: 23415907
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (MTX 10 mg/week plus LEF 20 mg/day without TGP)
Study: 17061632
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine 2 mg/kg with clonidine 2 microg/kg (group BUP+CLO)
Study: 17061632
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine 2 mg/kg (group BUP)
Study: 773180
Drug: Single antibiotic
Normalized name: BACITRACIN ZINC 500 [iU] in 1 g TOPICAL OINTMENT [Single Antibiotic]
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single antibiotic therapy
Study: 26272173
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin detemir
Study: 23317685
Drug: Buprenorphine-naloxone tablets
Normalized name: buprenorphine / naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-naloxone tablets
Study: 16951997
Drug: Tramadol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1 mg/kg intravenously over 2.5 min)
Study: 16951997
Drug: Tramadol (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (additional 0.33 mg/kg if pain relief was inadequate)
Study: 20558416
Drug: Indometacin (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (100-200 mg intramuscularly or orally)
Study: 20558416
Drug: Indometacin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (oral or intramuscular)
Study: 18216286
Drug: l‐NMMA (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐NMMA (0.2 mg . min(‐1) dl(‐1) forearm)
Study: 18216286
Drug: Aprepitant (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (375 mg orally)
Study: 12192262
Drug: Anti-inflammatory drugs
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory drugs
Study: 28914131
Drug: AbobotulinumtoxinA injections
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA injections (maximum total dose per injection cycle: 30 U/kg or 1000U) into the gastrocnemius-soleus complex and other muscles as required.
Study: 26030111
Drug: Inhalation challenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation challenges with terpenes and terpenoids
Study: 26030111
Drug: Intradermal challenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal challenges with volatile organic compounds (VOCs) including terpenes and terpenoids
Study: 26030111
Drug: Inhaled challenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled challenges
Study: 26030111
Drug: Intradermal challenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal challenges
Study: 21388456
Drug: Oral retinoids
Normalized name: tocopheryl retinoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral retinoids (dosages between 10 and 25 mg, with stepwise escalation)
Study: 21388456
Drug: Retinoids as
Normalized name: tocopheryl retinoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinoids as single agent therapy
Study: 14644692
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of CONSORT guidelines in behavioral medicine research
Study: 14644692
Drug: Behavioral medicine-specific
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral medicine-specific guidelines (e.g., treatment adherence)
Study: 10856098
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) 50 mg/m² IV on day 1 and Vinorelbine (VNB) 25 mg/m² IV on days 1 and 8 (arm 1)
Study: 10856098
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) 70 mg/m² IV on day 1 (arm 2)
Study: 10856098
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) 40 mg/m² IV on day 1 and Vinorelbine (VNB) 20 mg/m² IV on days 1 and 8 (arm 1) after dose reduction
Study: 10856098
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) 60 mg/m² IV on day 1 (arm 2) after dose reduction
Study: 7474314
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg suppository just after induction of anesthesia (Group T)
Study: 7474314
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg suppository about 90 min before incision (Group P)
Study: 2318223
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 60 mg
Study: 6985835
Drug: Chemoimmunotherapy (C.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy (C. parvum 4 mg subcutaneously weekly, along with chemotherapy)
Study: 6985835
Drug: Chemotherapy (vincristine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (vincristine, Daunorubicin, prednisone, Cytosine Arabinoside, and 6-mercaptopurine)
Study: 6985835
Drug: Intrathecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal methotrexate (13 mg/m2)
Study: 21270442
Drug: Lestaurtinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lestaurtinib (80 mg twice daily)
Study: 15529604
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day + ranitidine 150 mg/day
Study: 15529604
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day + 30 g alcohol/day
Study: 9664981
Drug: OKT3 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OKT3 treatment
Study: 7622343
Drug: Inositol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol (12 gm daily)
Study: 29949273
Drug: Warm normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm normal saline distention solution (0.9% normal saline warmed up to 36⁰C)
Study: 29949273
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature normal saline solution (0.9% normal saline at 25⁰C)
Study: 25934173
Drug: PARO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARO therapy group
Study: 9342764
Drug: LI 160
Normalized name: LIS-1
DrugBank: LIS-1 (DB18388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LI 160 (900 mg total daily dose)
Study: 9342764
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 mg total daily dose)
Study: 8213020
Drug: Cervical epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical epidural steroid/lidocaine injections (group A)
Study: 8213020
Drug: Steroid/lidocaine injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid/lidocaine injections into the posterior neck muscles (group B)
Study: 3924877
Drug: Mupirocin at
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin at 2 mg/l
Study: 3924877
Drug: Mupirocin at
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin at various concentrations (0.015 to 0.06 mg/l)
Study: 3924877
Drug: Mupirocin at
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin at 2-4 mg/l
Study: 3924877
Drug: Mupirocin at
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin at 16 mg/l
Study: 3924877
Drug: Mupirocin at
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin at 32 mg/l
Study: 3924877
Drug: Mupirocin at
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin at 1.0 mg/l or more for 120 h
Study: 3924877
Drug: Mupirocin at
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin at 4 mg/l
Study: 3924877
Drug: Mupirocin at
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin at 40 mg/l
Study: 3924877
Drug: 2% mupirocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mupirocin topical treatment
Study: 23677131
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of simvastatin (n=40)
Study: 21715526
Drug: Full-nut dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-nut dose (75 g/day mixed nuts)
Study: 21715526
Drug: Half-nut dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-nut dose
Study: 19302259
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (40 microg kg(‐1) min(‐1))
Study: 378735
Drug: Amoxycillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (1 g 8-hourly orally for fourteen days)
Study: 30390234
Drug: Dexlansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole 60 mg once daily (QD) during open-label healing phase
Study: 30390234
Drug: Dexlansoprazole 30
Normalized name: dexlansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole 30 mg QD during double-blind maintenance phase
Study: 30390234
Drug: Dexlansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole 60 mg QD
Study: 25622239
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone Duphaston(®) (2× 10mg) administered two times daily
Study: 25622239
Drug: Crinone 8%(®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8%(®) vaginal progesterone gel (90mg) administered daily
Study: 25622239
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone Duphaston(®)
Study: 25622239
Drug: Crinone 8%(®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8%(®) vaginal progesterone gel
Study: 21337584
Drug: Preparation with
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation with fasting, water, laxatives, and antiflatulents (Group I)
Study: 21337584
Drug: Preparation with
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation with fasting, water, and antiflatulents alone (Group II)
Study: 21337584
Drug: Preparation with
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation with fasting and water alone (Group III)
Study: 15048662
Drug: Psychological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatments for weight loss
Study: 9566644
Drug: T4 or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: T4 or T3 treatment for six months
Study: 7827931
Drug: Suture-ligation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suture-ligation of the branches of the inferior thyroid arteries at the thyroid capsule
Study: 2457767
Drug: alpha-human atrial
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-human atrial natriuretic peptide (alpha-hANP) infusion for 30 min
Study: 10638893
Drug: Morphine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.2 mg/kg)
Study: 21475254
Drug: Education on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education on smoking and oral health, vocational training on motivational interviewing, structured advice protocols
Study: 18341680
Drug: Performance-enhancing dietary
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Performance-enhancing dietary supplement (DS) with 21 mg synephrine and 304 mg caffeine
Study: 17947933
Drug: 250 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/kg fructose-1,6-diphosphate (FDP)
Study: 17947933
Drug: 2.5 mM
Normalized name: NeuroMatrix, 2.5 mm IDx2.5 cm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mM (1.4 g/L) fructose-1,6-diphosphate (FDP)
Study: 11292009
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine (30 mg/70 kg) at infusion rates of 2, 15, and 60 seconds
Study: 11292009
Drug: Intravenous hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydromorphone (3 mg/70 kg) at infusion rates of 2, 15, and 60 seconds
Study: 11292009
Drug: Placebo at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at infusion rates of 2, 15, and 60 seconds
Study: 9596428
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg pseudoephedrine
Study: 17138310
Drug: Moderate pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate pressure massage therapy
Study: 17138310
Drug: Light pressure
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light pressure massage therapy
Study: 21937367
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple treatment plus probiotic (lansoprazole, clarithromycin, amoxicillin, saccharomyces boulardii)
Study: 21937367
Drug: Levofloxacin-based therapy
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-based therapy (esomeprazole, levofloxacin, amoxicillin for 14 days)
Study: 21937367
Drug: Levofloxacin-based triple
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-based triple therapy (esomeprazole and amoxicillin for 5 days, followed by esomeprazole, levofloxacin, and metronidazole for 7 days)
Study: 12701116
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) at a dose of 2,400 mg per day
Study: 10939036
Drug: Theodrip (theophylline)
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theodrip (theophylline) 4.8 mg/kg
Study: 8627041
Drug: Combined live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V)
Study: 8627041
Drug: Measles-mumps-rubella and
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles-mumps-rubella and varicella vaccines at separate injection sites
Study: 2415097
Drug: Amino-oxyacetic acid
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino-oxyacetic acid (50 or 75 mg, four times a day orally for one week)
Study: 22606978
Drug: Lactulose (Gp‐L)
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose (Gp‐L)
Study: 17980550
Drug: Amitriptyline (10mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (10mg/day to start, dose elevation of 10mg/week up to 50mg/day if tolerated for eight weeks)
Study: 10523008
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg TU
Study: 10523008
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg TU
Study: 10523008
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg TU and 1000 mg TU
Study: 7491882
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g honey
Study: 7491882
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g honey
Study: 7491882
Drug: Glucose-fructose mixture
Normalized name: fructose / glucose / phosphoric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-fructose mixture (35 g each)
Study: 9505155
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g lactulose
Study: 6176313
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (5‐FU and methyl‐CCNU)
Study: 6176313
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (external radiotherapy of 5000 rad combined with chemotherapy)
Study: 24565386
Drug: Ondansetrone 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetrone 4 mg
Study: 24565386
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 5 mL
Study: 12148861
Drug: Interactive computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive computer displays with scene magnification initially set 5% higher than VOR gain, 10 sessions of 30 minutes twice daily for 5 days
Study: 10434216
Drug: Clonidine 0.2
Normalized name: CLONIDINE 0.2MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.2 mg (C2)
Study: 10434216
Drug: Clonidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.4 mg (C4)
Study: 10434216
Drug: Esmolol (E)
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esmolol (E) 300 micrograms.kg‐1 followed by a continuous infusion of 160 micrograms.kg‐1.min‐1
Study: 597688
Drug: Modelling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modelling and role‐rehearsal + daily social homework
Study: 29231316
Drug: Pregabalin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75 mg, twice a day)
Study: 23460328
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration therapy (WBVT) for 8 weeks starting from 1 month postoperatively
Study: 21278620
Drug: 20-mg IS-5-MN
Normalized name: IS 5-MN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-mg IS-5-MN tablet
Study: 17026606
Drug: Proview Eye
Normalized name: Proview Eye Pressure Monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proview Eye Pressure Monitor used three times daily for 30 days as an adjunct to the glaucoma regimen
Study: 17026606
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no change in treatment regimen during the study phase
Study: 9727991
Drug: Antibiotics (any)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (any)
Study: 9727991
Drug: More expensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More expensive antibiotics
Study: 9727991
Drug: Amoxycillin and
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin and folate inhibitors
Study: 785177
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of sodium-aescinat administered intravenously for 3 days
Study: 785177
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of aescinat administered for 6 days
Study: 23520221
Drug: High-intensity light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity light therapy
Study: 23520221
Drug: Low-intensity light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity light therapy
Study: 21875638
Drug: Chinese live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese live attenuated hepatitis A vaccine (H2 strain)
Study: 21875638
Drug: Domestic inactivated
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic inactivated hepatitis A vaccine (Healive(®))
Study: 21875638
Drug: Imported inactivated
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported inactivated hepatitis A vaccine (Havrix(®))
Study: 21875638
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (Control group)